Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | KDM4B | O94953 | 1/20 | 0.43 |
| ▸ | KDM5C | P41229 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.43 |
| ▸ | RELA | Q04206 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267798 | 0.81 | CYP19A1 (0.40) | MPLALDH1A1RAB9AKDM4ENPC1 | |
| SCHEMBL13078713 | 0.81 | KDM4E (0.42) | ALDH1A1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3742595 | 0.79 | TGFBR1 (0.48) | ALDH1A1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL1800719 | 0.78 | MPL (0.65) | MPLALDH1A1RAB9AALOX5MAPT | |
| SCHEMBL13045684 | 0.78 | TLR7 (0.41) | MPLALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL21484871 | 0.76 | MEN1 (0.54) | ALDH1A1RAB9AALOX5MAPTMEN1 | |
| SCHEMBL44739 | 0.73 | MPL (1.00) | MPLALDH1A1RAB9AALOX5MAPT | |
| SCHEMBL30122901 | 0.73 | MPL (1.00) | MPLALDH1A1RAB9AALOX5MAPT | |
| SCHEMBL24107604 | 0.72 | MPL (0.57) | MPLALDH1A1RAB9AALOX5MAPT | |
| SCHEMBL15624391 | 0.72 | TDP1 (0.44) | MAPTMEN1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2022-09-27 | — | — | US | disclosed |
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-03-10 | — | — | US | disclosed |
| CN-112351983-A | Substituted propionamides as inhibitors of nucleases | 马萨里克大学 | 2021-02-09 | — | — | CN | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| EP-3556756-B1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019201867-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019201867-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2019-10-24 | — | — | WO | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556756-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | Masarykova univerzita (CZ) | 2019-10-23 | — | — | EP | disclosed |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | BENTLEY JONATHAN | 2010-11-11 | — | — | US | disclosed |
| EP-2118097-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-20090042897-A1 | Chemical Compounds | GLAXO GROUP LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2008092891-A1 | 1-OXA-3-AZASPIRO(4.5)DECAN-2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092888-A1 | 1-OXA-3-AZASPIRO[4,5]DECAN--2-ONE DERIVATIVES FOR THE TREATMENT OF EATING DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073507-A1 | SUBSTITUTED PROPANAMIDES AS INHIBITORS OF NUCLEASES | DNASE1, RNASEH1, FEN1 | MPL 4852/4885ALDH1A1 1635/4885RAB9A 2621/4885 |
| US-20090042897-A1 | Chemical Compounds | NPY5R, NPY1R, NPY2R | MPL 519/4885ALDH1A1 3488/4885RAB9A 1618/4885 |
| US-11453663-B2 | Substituted propanamides as inhibitors of nucleases | DNASE1, RNASEH1, FEN1 | MPL 4852/4885ALDH1A1 1635/4885RAB9A 2621/4885 |
| US-20100286151-A1 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders | NPY5R, NPY1R, NPY4R | MPL 2051/4885ALDH1A1 3300/4885RAB9A 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.